Alpha 2.0
Login Register
» Articles » PMID: 23653981

Observational Study of the Safety of a Cluster Schedule for Subcutaneous Immunotherapy in a Pediatric Population

Overview
Journal J Investig Allergol Clin Immunol
Specialty Allergy & Immunology
Date 2013 May 10
PMID 23653981
Citations 3
Authors
A Penas
M Garcia-Gonzalez
M J Cruz
L Valdesoiro
J D Boot
H Larramona
O Asensio
R Grau
J Costa
M Bosque
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and safety of subcutaneous immunotherapy in asthmatic children allergic to house dust mite: a meta-analysis and systematic review.

Zheng C, Xu H, Huang S, Chen Z Front Pediatr. 2023; 11:1137478.

PMID: 37397157 PMC: 10310999. DOI: 10.3389/fped.2023.1137478.

A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Mosges R, Kasche E, Raskopf E, Singh J, Sohlich L, Astvatsatourov A Allergy. 2017; 73(4):896-904.

PMID: 29150857 PMC: 5947135. DOI: 10.1111/all.13358.

13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation.

Distler A, Pappelendam D Allergo J Int. 2016; 24:294-302.

PMID: 27069842 PMC: 4792348. DOI: 10.1007/s40629-015-0084-y.